For recurrent glioblastoma multiforme (GBM), the median overall survival was 8.63 months for patients treated with bevacizumab, an anti‐VEGF antibody, and 8.91 months when bevacizumab was combined with irinotecan, a chemotherapeutic agent [62] Thus, this study showed bevacizumab alone is beneficial for GBM. This evidence concerns the gene VEGFA and glioblastoma.